Pharmacy Times

JUNE 9, 2025

Still, confusion remains over the role of pharmacy and therapeutics (P&T) committees in this process. Tichy, PharmD, MBA, vice chair of pharmacy formulary for Mayo Clinic, explained. Presented at: American Society of Health-System Pharmacists 2025 Pharmacy Futures. REFERENCES 1. Updated March 20, 2023.

Compounding Pharmacies 56

Compounding Pharmacies FDA Hospitals Immunization 56

Pharmacy Times

JULY 9, 2025

SHOW MORE FDA approves a new dosing schedule for donanemab, enhancing safety and efficacy in treating early symptomatic Alzheimer disease. FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease. Mayo Clinic. 3 REFERENCES 1. Eli Lilly and Company.

Labelling 65

Labelling FDA Compounding Pharmacies Independent Pharmacies 65

Pharmacy Times

JUNE 26, 2025

In an interview with Pharmacy Times , Shaji Kumar, MD, consultant and research chair of the Division of Hematology in the Department of Internal Medicine at Mayo Clinic, discussed emerging data from the phase 2 RedirecTT-1 study (NCT04586426).

Compounding Pharmacies 65

Compounding Pharmacies Vaccines Immunization Mayo Clinic 65

Pharmacy Times

JULY 14, 2025

SHOW MORE FDA fast-tracks TRE-515 for advanced prostate cancer, combining it with radiation therapy to enhance treatment outcomes and patient care. The FDA has granted fast track designation to TRE-515 (Trethera Corporation), a novel drug, in combination with radiation therapy for the treatment of prostate cancer.

FDA 73

FDA Compounding Pharmacies Compounding Immunization 73

Drug Topics

JUNE 24, 2025

The FDA approved belimumab (Benlysta), a 200 mg/mL autoinjection, for subcutaneous injection in patients 5 years of age and older with active lupus nephritis who are receiving standard therapy. FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis. Mayo Clinic. REFERENCES 1. News release.

FDA 509

FDA Immunization Vaccines Mayo Clinic 509

Pharmacy Times

JUNE 24, 2025

The FDA approved an autoinjector of belimumab (Benlysta; GSK) for the subcutaneous injection in children aged 5 years and older with active lupus nephritis (LN) who are receiving standard therapy. FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis. Pharmacy Times. Pharmacy Times.

FDA 106

FDA Compounding Pharmacies Vaccines Immunization 106

Drug Topics

JULY 15, 2025

2 “These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women,” Regina Castaneda, MD, research fellow for the Division of Endocrinology at the Mayo Clinic, said in a release. said in a release.

Mayo Clinic 315

Mayo Clinic Specialty Pharmacies Compounding Independent Pharmacies 315

Pharmacy Times

JUNE 19, 2025

Standard-of-care treatment for patients with ALK fusions is alectinib (Alecensa; Genentech), a TKI that was approved by the FDA in 2024 for adjuvant treatment following tumor resection in patients with ALK-positive NSCLC. FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer. Updated April 22, 2025.

Chemotherapy 73

Chemotherapy Compounding Pharmacies Hospitals Immunization 73

Pharmacy Times

JUNE 15, 2025

Following, HR+, HER2- early breast cancer is a common subtype where the cancer cells have estrogen and progesterone receptors but do not have excessive amounts of the HER2 protein, according to Mayo Clinic. Mayo Clinic. Clinicaltrials.gov: NCT05306340. Updated April 15, 2025. Accessed June 13, 2025. News release.

Mayo Clinic 106

Mayo Clinic Compounding Pharmacies Immunization Compounding 106

Drug Topics

JULY 16, 2025

Mayo Clinic. Self-reported resilience during the COVID-19 pandemic. JAMA Netw Open. 2025;8(7):e2520360. doi:10.1001/jamanetworkopen.2025.20360 2025.20360 2. Resilience: Build skills to endure hardship. December 23, 2023. Accessed July 16, 2025. Nurture your resilience: bouncing back from difficult times. NIH News in Health. April 2022.

Specialty Pharmacies 315

Specialty Pharmacies Independent Pharmacies Compounding Vaccines 315

Pharmacy Times

JUNE 9, 2025

Mayo Clinic. Akkooi A, Mandala M, Kicinski M, Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation. J Clin Oncol. 43, 2025 (suppl 17; abstr LBA9500). doi:10.1200/JCO.2025.43.17_suppl.LBA9500.

Compounding Pharmacies 82

Compounding Pharmacies Immunization Mayo Clinic Compounding 82

Pharmacy Times

JULY 18, 2025

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. JAMA Netw Open. 2025;8(7):e2520011. doi:10.1001/jamanetworkopen.2025.20011 2025.20011 2. Long-term obesity and biological aging in young adults.

Compounding Pharmacies 73

Compounding Pharmacies Compounding Immunization Mayo Clinic 73

Pharmacy Times

JULY 14, 2025

The ADVANTAGE AF trial supported the FDA approval, showing 99.7% The FDA approved a label extension for the Farapulse Pulsed Field Ablation (PFA) system (Boston Scientific) to now include approval for the system in the treatment of drug-refractory, symptomatic persistent atrial fibrillation (AF). Mayo Clinic.

Labelling 65

Labelling FDA Compounding Pharmacies Hospitals 65